Test Price
1,400 AED✅ Home Collection Available
POL Gene Mutation Analysis (Tumor Tissue) in Dubai | 1400 AED | DHA Licensed
Executive Summary & Core Metrics
Test Overview & Methodology
POL gene mutation analysis using Sanger sequencing identifies pathogenic variants in DNA polymerase genes (commonly POLE and POLD1) from tumor tissue. This assay aids prognosis and guides immunotherapy selection in advanced cancers such as endometrial, colorectal, and bladder malignancies. The test is essential for oncologists, gynecologists, and pathologists managing patients with suspected ultramutated tumors linked to improved checkpoint inhibitor response.
| Feature | Our Test (POL Gene Mutation Analysis) | Closest Alternative (NGS Panel) |
|---|---|---|
| Precision | Gold‑standard Sanger sequencing – reads every base | Next‑Generation Sequencing with inferior read depth at GC‑rich regions |
| Turnaround | 8–9 days | 10–14 days |
| Cost (AED) | 1,400 | 2,000–3,500 |
| Sample | Tumor tissue (FFPE acceptable) | Blood only (germline) or fresh tumor |
Physician Insight & Safety Protocols
“POL gene mutation results must be interpreted within the full clinical and histological context. This molecular data is a powerful adjunct to multidisciplinary tumour board decisions and never replaces comprehensive oncologic judgment.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
⚠ Medication Warning
Do not discontinue any prescribed medication or modify your treatment plan based solely on this test result. Always consult your treating physician.
Exclusion Criteria & Emergency Red Flags
- Insufficient sample: Tumor tissue weight less than 5 mg, severe necrosis, or improper fixation.
- Coagulopathy: Patients with uncontrolled bleeding disorders precluding safe biopsy.
- Recent chemotherapy: Samples taken within 14 days of systemic therapy may yield degraded DNA.
- Pregnancy: Test not indicated for routine prenatal screening; requires genetic counseling referral.
🚨 If after biopsy you experience high fever, severe pain, active bleeding, or rapid swelling, seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is POL gene mutation analysis and who needs it?
This test detects mutations in the POLE and POLD1 genes from a tumor tissue sample. It is recommended for patients with advanced or recurrent cancers, particularly endometrial, colorectal, and bladder tumors, to identify those likely to respond exceptionally well to immune checkpoint inhibitors.
2. How does a positive result affect my treatment?
A positive result indicates your tumor harbors an ultramutated phenotype, often correlating with a high tumor mutational burden (TMB). This can make the cancer more vulnerable to immunotherapy drugs such as pembrolizumab or nivolumab. Your oncologist will integrate this data with other biomarkers to tailor your treatment plan.
3. What sample is required and how is it collected?
The test requires a solid tumor tissue specimen, preferably a formalin-fixed, paraffin-embedded (FFPE) block or unstained slides. Collection is performed exclusively within an accredited hospital setting via biopsy or surgical resection. Home phlebotomy is not applicable; our secure medical courier service retrieves the archival specimen from the hospital or pathology lab.
UAE Regulatory & Data Privacy Adherence
- Full adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the use of information and communication technology in health fields.
- Clinical safety and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory operations are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) under DHA Facility License 1143.
Clinical & Logistical Metadata
| Test Name | POL Gene Mutation Analysis (Tumor Tissue) |
| Price (AED) | 1,400 |
| Turnaround Time | 8–9 working days |
| Sample Type / Matrix | Archival tissue specimen (FFPE block or unstained slides) – Hospital extraction only; mobile home phlebotomy disabled for safety. |
| Methodology Used | Sanger sequencing of POLE/POLD1 exons |
| ICD-10-CM Code | C80.1 (Malignant neoplasm without specification of site) |
| LOINC Code | 81247-9 (Gene mutation analysis in Tumor tissue) |
| DHA Facility License & Laboratory Address | License 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians